In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent
epithelial ovarian, fallopian tube, or primary peritoneal
cancer who were in complete or partial response to platinum - based chemotherapy were
treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).
The LION trial randomized 650 patients with advanced
epithelial ovarian cancer and macroscopic complete resection to either systematic pelvic and para-aortic LNE (323 patients in intention - to -
treat cohort), or no LNE (324 patients in intention - to -
treat cohort).